Department of Health and Human Services
National Institutes of Health
Toggle navigation
Search
Home
About the Clinical Center
Clinical Trials & You
Participate in a Study
Referring a Patient
How to Search
Contact Us
Search the Studies
Go Back
Searched Result
198 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number
Title
Protocol Status
Min-Max Age
Institute
Keywords
20-C-0162
A Phase 1 Study of Venetoclax with Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Liver Lymphoma
17-C-0048
Anti-CD30 CAR T Cells with Fully-human Binding Domains for Treating CD30-expressing Lymphomas Including Anaplastic Large Cell Lymphomas
Completed Study; data analyses ongoing
18-73 Years
NCI
Liver Lymphoma
09-I-0102
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver Lymphoma
93-I-0063
Study of the Immunopathogenesis, Natural History, and Genetics of Autoimmune Lymphoproliferative Syndrome (ALPS) Associated with an Expansion of CD4-8-/TCR alpha/beta+ T Cells
Participants currently recruited/enrolled
0-99 Years
NIAID
Liver Lymphoma
001125-DK
Optimizing HBV Care Cascade among Foreign-Born in the United States (FOCUS-HBV Study)
Participants currently recruited/enrolled
18-100 Years
NIDDK
Liver
001109-C
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Participants currently recruited/enrolled
8-125 Years
NCI
Liver
001018-CH
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C
Participants currently recruited/enrolled
0-125 Years
NICHD
Liver
000958-C
Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment
Enrolling by Invitation
18-125 Years
NCI
Liver
000957-HG
A Phase 1/2, Open-Label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of SEL-302 (MMA-101 following administration of SEL-110) in Pediatric Subjects with Mut Subtype Isolated Methylmalonic Acidemia (MMA)
Participants currently recruited/enrolled
3-17 Years
NHGRI
Liver
000923-H
Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors
Participants currently recruited/enrolled
18-110 Years
NHLBI
Lymphoma
000826-C
An Open Label, Randomised, Phase 2 Study to Evaluate the Safety and Efficacy of MTL-CEBPA Administered in Combination with Sorafenib or Sorafenib Alone, in TKI Naive Participants with Previously Treated Advanced Hepatocellular Carcinoma (HCC) and Hepatit
Recruitment has not started
18-125 Years
NCI
Liver
000784-N
Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects
Participants currently recruited/enrolled
18-125 Years
NINDS
Liver
000686-CH
Intrathecal 2-Hydroxypropyl-Beta-Cyclodextrin for Neurological Decline in Patients with Niemann-Pick Disease Type C1
Participants currently recruited/enrolled
18-125 Years
NICHD
Liver
000665-DK
A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000633-C
Phase 1/2 Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000631-C
Investigation of the Cognitive Aftereffects of Neurotoxicity in Children and Young Adults with Relapsed/Refractory Hematologic Malignancies who Receive CAR T-cell Therapy
Recruitment has not started
5-125 Years
NCI
Lymphoma
000613-C
Phase I/II Trial to Determine the Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination with Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis after Reduced Intensity Conditioning and Peripheral Blood St
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
000545-DK
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant: A Prospective Natural History Study
Recruitment has not started
3-125 Years
NIDDK
Liver
000516-C
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma involving the Central Nervous System
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000494-DK
Natural History of Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000491-C
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
000489-C
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
Clinical hold/Recruitment or enrollment suspended
12-125 Years
NCI
Lymphoma
000479-H
Observational Study to Deeply Phenotype Major Organs in Sickle Cell Disease After Curative Therapies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Liver
000473-C
A Randomized Phase II Study of Systemic Chemotherapy with or without HAI FUDR-Dexamethasone in Patients with Unresectable Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
000444-H
Vaccine Responses in Patients with B Cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphoma
000387-H
The Natural History of Acquired and Inherited Bone Marrow Failure Syndromes.
Participants currently recruited/enrolled
2-125 Years
NHLBI
Liver
000337-C
Natural History Study of KSHV-Associated Multicentric Castleman's Disease
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000326-H
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX- 2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphoma
000324-C
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-35 Years
NCI
Lymphoma
000307-C
Phase II Study Evaluating the Efficacy of M9241 in Combination with Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects with Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
000274-C
Phase I Trial of Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000236-I
A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
000193-C
Phase 1 Study of Copanlisib with Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and other High-Grade B-cell Lymphomas
Clinical hold/Recruitment or enrollment suspended
18-125 Years
NCI
Lymphoma
000137-CH
Implications of Maternal 45,X Mosaicism As A Secondary Genomic Finding Following Cell-free DNA Sequencing During Pregnancy: A Deep Phenotype Study
Recruitment has not started
18-99 Years
NICHD
Liver
000130-DK
Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000118-DK
Prospective Cohort Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects with Chronic Liver Disease
Participants currently recruited/enrolled
18-100 Years
NIDDK
Liver
000115-C
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants with Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants with Solid Tumors on PD1/PDL1 Inhibitor Therapy, Including Booster D
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
000080-C
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
000079-DK
The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
000067-C
Understanding the Patient Experience: Symptom Burden in Pediatric Patients Receiving Chimeric Antigen Receptor (CAR) T-cell Therapy
Participants currently recruited/enrolled
2-125 Years
NCI
Lymphoma
000036-AA
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Study of Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
Participants currently recruited/enrolled
21-65 Years
NIAAA
Liver
21-C-0030
Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
21-C-0023
A Phase I Study of Pomalidomide and Nivolumab in Patients with Virus-Associated Malignancies With or Without HIV
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
21-C-0014
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
20-N-0019
The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease
Participants currently recruited/enrolled
18-125 Years
NINDS
Lymphoma
20-H-0141
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Enrolling by Invitation
18-125 Years
NHLBI
Liver
20-H-0021
Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag
No longer recruiting/follow-up only
2-125 Years
NHLBI
Liver
20-H-0016
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Lymphoma
20-DK-0079
A Randomized, Double-Blinded, Placebo-Controlled Study of REGN4661, A Leptin Receptor Agonist Antibody, In Patients with Generalized Lipodystrophy
No longer recruiting/follow-up only
12-125 Years
NIDDK
Liver
20-DK-0067
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment i
No longer recruiting/follow-up only
18-125 Years
NIDDK
Liver
20-CH-0165
Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals with Androgen Insensitivity
Participants currently recruited/enrolled
0-99 Years
NICHD
Liver
20-CC-0039
A Feasibility Study to Evaluate the Combination of Electromagnetic Tracking and Optical Imaging with Indocyanine Green (ICG) for Hepatic Biopsies
Enrolling by Invitation
18-125 Years
CC
Liver
20-C-0152
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
20-C-0127
A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), dexamethasone, and lenalidomide (RAdR) for relapsed/refractory T-cell malignancies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
20-C-0062
A phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
20-C-0028
Phase 1/2 Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults with Relapsed/Refractory Acute Myeloid Leukemia
Participants currently recruited/enrolled
3-35 Years
NCI
Liver
20-C-0022
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC)
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
20-C-0011
Phase 1 Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
20-C-0006
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
19-H-0139
Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.
Participants currently recruited/enrolled
18-125 Years
NHLBI
Liver
19-H-0057
Multiple Patient Program for Lamprene (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections- CLAM320B2002M
Participants currently recruited/enrolled
18-99 Years
NHLBI
Liver
19-H-0001
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients that are Treatment Na(SqrRoot) ve or Receiving Bruton s-tyrosine Kinase Inhibitor (BTK-I) Therapy
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
19-DK-0072
Non-Alcoholic Fatty Liver Disease, the Hepatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
19-DK-0067
Effect of Low Fat versus Low Carbohydrate Diets on Energy Metabolism
Completed Study; data analyses ongoing
18-50 Years
NIDDK
Liver
19-CH-0071
An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children with Growth Hormone Excess
Participants currently recruited/enrolled
2-18 Years
NICHD
Liver
19-C-0116
A Phase 2 Study of Acalabrutinib with DA-EPOCH-R or R-CHOP for Patients with Untreated Diffuse Large B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
19-C-0112
Phase I/II Study De-intensifying Exposure of Post-transplantation Cyclophosphamide as GVHD Prophylaxis after HLA-haploidentical Hematopoietic Cell Transplantation for Hematologic Malignancies
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
19-C-0103
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas with Secondary Involvement of the Central Nervous System (CNS)
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
19-C-0094
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
19-C-0085
Phase II Trial of Allogeneic Hematopoietic Cell Transplantation for Peripheral T cell Lymphoma
Clinical hold/Recruitment or enrollment suspended
12-125 Years
NCI
Lymphoma
19-C-0076
A Phase 1 Study of Interleukin-15 in Combination with Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
19-C-0039
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
19-C-0033
Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
19-C-0030
A Phase 2 Study of Response-Adapted Therapy with Copanlisib and Rituximab in Untreated Follicular Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
18-H-0004
Low Dose Danazol for the Treatment of Telomere Related Diseases
Participants currently recruited/enrolled
3-125 Years
NHLBI
Liver
18-EI-0068
An Investigation of Vitamin A Palmitate Supplementation in Patients with Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation
Participants currently recruited/enrolled
50-125 Years
NEI
Liver
18-EI-0067
An Investigation of Vitamin A Palmitate Supplementation in Patients with Age-Related Macular Degeneration (and without reticular pseudodrusen) and Delayed Dark Adaptation
Participants currently recruited/enrolled
50-125 Years
NEI
Liver
18-DK-N071
Early Tracking of Childhood Health Determinants Study
Participants currently recruited/enrolled
0-125 Years
NIDDK
Liver
18-DK-0123
Treatment of Chronic Delta Hepatitis with Lonafarnib, Ritonavir and Lambda Interferon
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
18-DK-0091
Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
18-C-0126
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)
Completed Study; data analyses ongoing
1-21 Years
NCI
Lymphoma
18-C-0122
Phase 1B Study of Copanlisib in Combination with Nivolumab or with Nivolumab and Ipilimumab
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
18-C-0059
Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Lymphoma
18-C-0024
A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy with Floxuridine and Dexamethasone in Combination with Systemic Chemotherapy for Patients with Colorectal Cancer Metastatic to the Liver
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
17-H-0118
A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
17-DK-0054
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment with Beta3-Adrenergic Receptor Agonists
Participants currently recruited/enrolled
18-40 Years
NIDDK
Liver
17-DK-0013
Therapeutic Targets in African-American Youth with Type 2 Diabetes
Participants currently recruited/enrolled
12-25 Years
NIDDK
Liver
17-DA-0093
Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder via Microbiota Investigations: A Pilot Study
Completed Study; data analyses ongoing
21-70 Years
NIDA
Liver
17-C-0164
A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Rituximab or Rituximab + Chemotherapy in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
17-C-0156
Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
17-C-0149
Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL),and Other Extranodal Diffuse Large B-cell Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
17-C-0137
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
Enrolling by Invitation
3-65 Years
NCI
Lymphoma
17-C-0127
Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
17-C-0125
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
17-C-0105
Prospective Study of Clonal Evolution in Follicular Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
17-C-0045
A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-DK-0143
Idiosyncratic Liver Injury Associated with Drugs (ILIAD): A Retrospective Study
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
16-DK-0038
A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients with Partial Lipodystrophy with an Open-Label Extension
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
16-CC-0049
A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment with Transarterial Embolization (TAE) Alone or Combined with Thermal Ablation
Enrolling by Invitation
18-125 Years
CC
Liver
16-C-0171
Phase I/II Study of Lenalidomide Combined with Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0135
A Pilot Study of Combined Immune Checkpoint Inhibition in combination with Ablative Therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
No longer recruiting/follow-up only
18-125 Years
NCI
Liver
16-C-0066
Phase I Study of MK-3475 (Pembrolizumab) in Patients with Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0062
A Phase I Study of Subcutaneous Recombinant Human IL-15 (S.C. Rhil-15) and Alemtuzumab for Patients with Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
16-C-0061
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
16-C-0054
T Cells Expressing a Fully-human Anti- CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
No longer recruiting/follow-up only
18-73 Years
NCI
Lymphoma
15-H-0172
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
15-H-0016
A Phase II Study Using ACP-196 in Patients with Relapsed/Refractory and Treatment Naive Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response.
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
15-DK-0174
Dynamic Post-Prandial Metabolism in Patients with Non-Alcoholic Fatty Liver Disease
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0170
Treatment of Chronic Delta Hepatitis with Lonafarnib and Ritonavir
Completed Study; data analyses ongoing
18-99 Years
NIDDK
Liver
15-DK-0143
Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected with Different Hepatitis C Virus Genotypes During Therapy with Sofosbuvir and GS-5816
Completed Study; data analyses ongoing
18-80 Years
NIDDK
Liver
15-DK-0108
Natural History of Noncirrhotic Portal Hypertension
Participants currently recruited/enrolled
12-125 Years
NIDDK
Liver
15-DK-0100
A Multidisciplinary Approach to Deciphering the Mechanisms Involved In Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0082
Mechanisms Associated with Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)ide Analogue Treatment in Patients with Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0079
Observational Study of Hepatitis B Virus (HBV) in Patients Coinfected with Human Immunodeficiency Virus (HIV)
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
15-DK-0003
Compassionate Use of Metreleptin in Previously-Treated Patients with Generalized Lipodystrophy
Participants currently recruited/enrolled
0-125 Years
NIDDK
Liver
15-DK-0002
Compassionate Use of Metreleptin in Previously-Treated Patients with Partial Lipodystrophy
No longer recruiting/follow-up only
0-125 Years
NIDDK
Liver
15-C-0138
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients with Newly Diagnosed Glioblastoma
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
15-C-0078
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated with a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
No longer recruiting/follow-up only
18-65 Years
NCI
Lymphoma
15-C-0067
A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
15-C-0029
Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults with Recurrent or Refractory CD22-expressing B Cell Malignancies
Participants currently recruited/enrolled
3-39 Years
NCI
Lymphoma
14-HG-0071
Clinical and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation
Participants currently recruited/enrolled
1-80 Years
NHGRI
Liver
14-HG-0055
Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders
Completed Study; data analyses ongoing
2-80 Years
NHGRI
Liver
14-H-0155
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease
No longer recruiting/follow-up only
18-50 Years
NHLBI
Liver
14-C-0161
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
14-C-0157
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
14-C-0004
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
13-N-0135
Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)
Completed Study; data analyses ongoing
18-125 Years
NINDS
Lymphoma
13-I-0062
A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects
Completed Study; data analyses ongoing
18-65 Years
NIAID
Liver
13-H-0116
A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients
Participants currently recruited/enrolled
4-125 Years
NHLBI
Lymphoma
13-H-0060
Analysis of Samples Collected from a Subject who Received ACP- 501 (Human Recombinant Lecithin:Cholesterol Acyltransferase [rhLCAT])
Completed Study; data analyses ongoing
18-100 Years
NHLBI
Liver
13-DK-0091
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir DF versus Tenofovir DF Monotherapy in HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
13-DK-0057
Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake
Completed Study; data analyses ongoing
14-70 Years
NIDDK
Liver
13-C-0118
A Phase I/II Trial of TRC102 (methoxyamine HCl) in Combination with Temozolomide in Patients with Relapsed Solid Tumors and Lymphomas
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
12-H-0092
An Intravenous, Open-Label, Single-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of rhLCAT in Patients with Stable Coronary Artery Disease
Completed Study; data analyses ongoing
30-75 Years
NHLBI
Liver
12-H-0035
A Phase II study of Ibrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Need Therapy and are Older than 65 or have a 17p Deletion
No longer recruiting/follow-up only
18-125 Years
NHLBI
Lymphoma
12-DK-0071
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults with Chronic Hepatitis B
Completed Study; data analyses ongoing
18-40 Years
NIDDK
Liver
12-C-0193
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
12-C-0175
Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets
Completed Study; data analyses ongoing
18-125 Years
NCI
Liver
12-C-0112
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults with B Cell Malignancies
Completed Study; data analyses ongoing
1-30 Years
NCI
Lymphoma
11-I-0109
Viral Infections in Healthy and Immunocompromised Hosts
Participants currently recruited/enrolled
0-125 Years
NIAID
Liver
11-DK-0151
Withdrawal of Therapy After Long-Term Oral Nucleos(t)ide Analogue Treatment in Patients with Chronic Hepatitis B
Completed Study; data analyses ongoing
18-125 Years
NIDDK
Liver
11-DK-0108
Observational Study of Persons with Hepatitis B Virus Infection in North America (Cohort Study)
Completed Study; data analyses ongoing
18-100 Years
NIDDK
Liver
11-CC-0152
The Natural History of Liver Disease in a Cohort of Participants with Hepatitis B and/or Hepatitis C with or without HIV Infection
Completed Study; data analyses ongoing
18-99 Years
CC
Liver
11-C-0242
Collection of Blood from Patients with Cancer, Other Tumors, or Tumor Predisposition Syndromes for Analysis of Genetic Differences in Drug Disposition
Participants currently recruited/enrolled
3-125 Years
NCI
Lymphoma
11-C-0220
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) Incorporating Pilot Evaluation of KSHV Targeted Therapies
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
11-C-0112
Acquisition of Blood and Tumor Tissue Samples from Patients with Gastrointestinal Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
11-C-0061
Phase I Trial of Z-Endoxifen in Adults with Refractory Hormone Receptor-Positive Breast Cancer, Desmoid Tumors, Gynecologic Tumors, or other Hormone Receptor-Positive Solid Tumors
No longer recruiting/follow-up only
18-125 Years
NCI
Liver
10-H-0141
A Phase II Study of Ofatumumab-Based Induction Chemoimmunotherapy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
No longer recruiting/follow-up only
18-99 Years
NHLBI
Lymphoma
10-CC-0217
A Comparison of Methods for Assisting Needle Angle Selection During Image-Guided Tissue Biopsy
Completed Study; data analyses ongoing
18-125 Years
CC
Liver
10-C-0201
Apheresis and CD34+ Selection of Mobilized Peripheral Blood CD34+ Cells from Patients with DOCK8 Deficiency, LAD-1, and GATA2 Deficiency
Participants currently recruited/enrolled
18-40 Years
NCI
Liver
10-C-0066
A Study of Hairy Cell and other Leukemias with a Focus on Recombinant Immunotoxins for Cancer Treatment
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
10-C-0056
A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
10-C-0054
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells from the Original Transplant Donor to Patients with Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
No longer recruiting/follow-up only
18-75 Years
NCI
Lymphoma
10-C-0025
Randomized Phase II Trial of Rituximab with Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
10-C-0011
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
09-I-0013
Biomarkers of Inflammation, Coagulation, and Endothelial Function in HIV-Infected Adults
Enrolling by Invitation
18-100 Years
NIAID
Liver
09-DK-0097
Vitamin E Pharmacokinetics and Biomarkers in Normal and Obese Women
Completed Study; data analyses ongoing
18-55 Years
NIDDK
Liver
09-C-0053
Autologous and Related/Unrelated Allogeneic Hematopoietic Stem Cell Transplant and Cellular Therapies Data Submission and Research Sample Collection to the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Don
Enrolling by Invitation
1-125 Years
NCI
Lymphoma
08-H-0186
Safety and the Anti- Tumor Effects of Escalating Doses of Adoptively Infused Ex Vivo Expanded Autologous Natural Killer (NK) Cells Against Metastatic Cancers or Hematological Malignancies Sensitized to NK-TRAIL Cytotoxicity with Bortezomib
Completed Study; data analyses ongoing
18-70 Years
NHLBI
Lymphoma
08-H-0105
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Participants currently recruited/enrolled
18-125 Years
NHLBI
Lymphoma
08-DK-0149
High Dose Ribavirin in Combination with Peginterferon for Patients with Chronic Hepatitis C Genotype 1 Infection Who Have Failed to Respond or Relapsed after Standard Therapy
Completed Study; data analyses ongoing
18-65 Years
NIDDK
Liver
08-DK-0098
Natural History of Familial Carcinoid Tumor
Participants currently recruited/enrolled
18-125 Years
NIDDK
Liver
07-C-0195
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Trea
Completed Study; data analyses ongoing
18-74 Years
NCI
Lymphoma
06-I-0153
A Pilot Study of Hepatic Fibrosis in HIV/AIDS Patients with Chronically Elevated Transaminases on Antiretroviral Therapy
No longer recruiting/follow-up only
18-100 Years
NIAID
Liver
06-I-0015
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
Participants currently recruited/enrolled
0-125 Years
NIAID
Lymphoma
06-H-0217
Genetic Disorders of Mucociliary Clearance
Completed Study; data analyses ongoing
2-65 Years
NHLBI
Liver
06-C-0213
Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)
Participants currently recruited/enrolled
0-125 Years
NCI
Lymphoma
06-C-0150
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
06-AR-0198
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
Completed Study; data analyses ongoing
8-100 Years
NIAMS
Liver
05-H-0130
Long-Term Evaluation and Follow Up Care of Patients Treated with Allogeneic Stem Cell Transplants
Participants currently recruited/enrolled
7-80 Years
NHLBI
Liver
05-CC-0091
Electromagnetic Tracking of Devices During Interventional Procedures
Enrolling by Invitation
18-125 Years
CC
Liver
05-C-0252
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas
Completed Study; data analyses ongoing
18-125 Years
NCI
Lymphoma
04-HG-0127
Clinical and Basic Investigations of Methylmalonic Acidemia (MMA) and Related Disorders
Participants currently recruited/enrolled
0-125 Years
NHGRI
Liver
04-C-0274
Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
04-C-0102
Hematologic Malignancy Biology Study
Enrolling by Invitation
1-75 Years
NCI
Lymphoma
03-H-0282
Characterization of Cardiac Function in Subjects with Hereditary Hemochromatosis Who Are New York Heart Association Functional Class I
Completed Study; data analyses ongoing
21-100 Years
NHLBI
Liver
03-C-0066
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene, and Characterization of the Predisposition to Renal Cancer
Participants currently recruited/enrolled
2-125 Years
NCI
Liver
02-I-0286
Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients with Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome
Participants currently recruited/enrolled
2-125 Years
NIAID
Lymphoma
02-I-0086
Evaluation of Viral Factors and Immune Parameters to Study HIV-Specific Immunity
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
02-H-0250
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning with Campath-1H
Completed Study; data analyses ongoing
18-125 Years
NHLBI
Lymphoma
02-DK-0022
Long-Term Efficacy of Leptin Replacement in Treatment of Lipodystrophy
Completed Study; data analyses ongoing
1-125 Years
NIDDK
Liver
02-C-0210
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy
Participants currently recruited/enrolled
0-125 Years
NCI
Lymphoma
02-C-0179
Biospecimen Acquisition from Human Subjects
Participants currently recruited/enrolled
18-125 Years
NCI
Liver
01-I-0238
Host Response to Infection and Treatment in Leishmania Infection of Humans
Participants currently recruited/enrolled
3-100 Years
NIAID
Liver
01-CC-0045
Studies of Phlebotomy Therapy in Hereditary Hemochromatosis
Participants currently recruited/enrolled
18-125 Years
CC
Liver
01-C-0038
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-Related Pre-Malignant Lesions, and/or Cancer
Participants currently recruited/enrolled
18-125 Years
NCI
Lymphoma
01-C-0030
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
No longer recruiting/follow-up only
18-125 Years
NCI
Lymphoma
99-H-0050
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients with Debilitating Hematologic Diseases
Completed Study; data analyses ongoing
2-80 Years
NHLBI
Lymphoma
96-C-0071
Follow-up for Patients Previously Enrolled on the Center for Cancer Research Protocols
No longer recruiting/follow-up only
0-125 Years
NCI
Lymphoma
94-C-0074
Treatment and Natural History Study of Lymphomatoid Granulomatosis
Participants currently recruited/enrolled
12-125 Years
NCI
Lymphoma
93-I-0119
Detection and Characterization of Host Defense Defects
Participants currently recruited/enrolled
0-125 Years
NIAID
Liver
93-C-0133
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children with Previously Untreated Patients with Aggressive Non-Hodgkin's Lymphoma
No longer recruiting/follow-up only
12-125 Years
NCI
Lymphoma
91-I-0140
Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in HIV-Infected and HIV-Uninfected Volunteers
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver
91-DK-0214
Evaluation of Patients with Liver Disease
Participants currently recruited/enrolled
2-125 Years
NIDDK
Liver
91-CC-0117
Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection in a Blood Donor Population
No longer recruiting/follow-up only
18-125 Years
CC
Liver
87-DK-0029
Diagnosis and Treatment of Patients with Cystic Fibrosis
Participants currently recruited/enrolled
4-125 Years
NIDDK
Liver
85-H-0105
Cardiovascular Evaluation of Homozygous Familial Hypercholesterolemia
Completed Study; data analyses ongoing
2-70 Years
NHLBI
Liver
81-I-0164
Procedures to Obtain Plasma, Lymphocytes, or Other Specimens for Research Studies
Participants currently recruited/enrolled
18-125 Years
NIAID
Liver